Business
Equillium to Participate in the Cantor Global Healthcare Conference 2025
LA JOLLA, Calif., August 29, 2025--Equillium to Participate in the Cantor Global Healthcare Conference 2025
About this update from Equillium, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":8918,"height":3592,"url":"https://media.zenfs.com/en/business-wire.com/eea0f6e536c088d21842a9d6a5fd311c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/COQ7RIqPeMRFZU2tD8jTRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/eea0f6e536c088d21842a9d6a5fd311c","width":960,"height":387},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/zN5BiIeLH01dkGeYS1wzjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NjY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/eea0f6e536c088d21842a9d6a5fd311c","width":1200,"height":483}},"lazy":false},{"type":"text","content":"LA JOLLA, Calif., August 29, 2025--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Friday, September 5, 2025 at 7:55am ET.","length":348,"tagName":"p"},{"type":"text","content":"Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.","length":145,"tagName":"p"},{"type":"text","content":"Investors and the general public are invited to listen to a live webcast of the presentation on the Events & Presentations page, located under the Investor Relations section on equilliumbio.com. An archived replay of both presentations will be available for 90 days.","length":270,"tagName":"p"},{"type":"text","content":"About Equillium","length":15,"tagName":"p"},{"type":"text","content":"Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other anti-inflammatory and immunomodulatory agents. EQ504’s preclinical properties provide the potential for targeted, local delivery for the treatment of ulcerative colitis and pouchitis or inhaled formulations for the treatment of pulmonary diseases.","length":584,"tagName":"p"},{"type":"t...